For research and educational purposes only. Not intended for human consumption.
Kisspeptin
Well Researched- •Fertility treatment potential documented
- •Reproductive disorder diagnostic tool
- •GnRH stimulation mechanisms clarified
Master Reproductive Regulator | GnRH Stimulator
Overview
What is Kisspeptin?
Kisspeptin is a family of neuropeptides encoded by the KISS1 gene that acts as a master regulator of the reproductive system. It potently stimulates gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, making it critical for puberty onset, fertility, and reproductive function. Kisspeptin-54 (the full-length form) and shorter fragments like kisspeptin-10 are being studied for fertility treatments and as diagnostic tools for reproductive disorders.
Key Benefits
Potent LH/FSH stimulation within minutes, diagnostic tool for reproductive disorders, fertility treatment potential, physiological approach to hormone modulation.
Mechanism of Action
Kisspeptin binds to KISS1R (GPR54) receptors on GnRH neurons in the hypothalamus, triggering robust GnRH release. This causes rapid downstream LH and FSH secretion from the pituitary, stimulating gonadal function. The kisspeptin system integrates metabolic, stress, and photoperiod signals to regulate reproduction.
Molecular Information
Pharmacokinetics
Research Indications
Oocyte Maturation Trigger
Alternative to hCG for final oocyte maturation in IVF, with dramatically reduced OHSS risk.
Hypothalamic Amenorrhea
Restores pulsatile LH secretion in women with functional hypothalamic amenorrhea.
Male Hypogonadism Assessment
Diagnostic tool to differentiate hypothalamic vs pituitary causes of hypogonadism.
Research Protocols
Disclaimer: Kisspeptin is investigational for most uses. IVF trigger protocols should only be administered under specialist supervision. Consult a reproductive endocrinologist.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| IVF Oocyte Trigger | 6.4 nmol/kg | Single SC dose | Subcutaneous |
| Male Fertility Assessment | 1 nmol/kg | Single IV bolus | Intravenous |
| Hypothalamic Amenorrhea | 6.4 nmol/kg | Twice weekly | Subcutaneous |
| Research Protocol | 0.3-1 nmol/kg | IV bolus or infusion | Intravenous |
Timing: For IVF trigger, administered 34-36 hours before egg retrieval. Effects on LH begin within minutes and peak at 4-6 hours.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temperature
Add sterile water or bacteriostatic water slowly
Gently swirl to dissolve - do not shake
Solution should be clear and colorless
For IV use, further dilute in saline as needed
Store reconstituted solution refrigerated
Use within 24 hours for IV, 7 days for SubQ
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Pharmaceutical-grade source
For clinical applications, use GMP-manufactured kisspeptin.
Clear solution
Reconstituted kisspeptin should be clear and particle-free.
Proper storage
Maintain cold chain at 2-8°C.
Research use only
Most kisspeptin is sold for research purposes only.
Cloudy or discolored
Indicates degradation - do not use.
What to Expect
- •Minutes: LH begins to rise within 15-30 minutes of administration
- •Hours 1-6: Peak LH response at 4-6 hours
- •Hours 6-24: Gradual return to baseline
- •For fertility: Oocyte maturation triggered for retrieval 34-36 hours post-dose
- •Side effects: Generally well-tolerated, mild injection site reactions possible
Side Effects & Safety
Side Effects
- •Generally well-tolerated in clinical trials
- •Dramatically reduced OHSS risk compared to hCG trigger
- •May cause mild injection site reactions
- •Transient flushing or warmth reported in some subjects
- •Should be used under specialist supervision for fertility applications
- •Not recommended during pregnancy
When to Stop
- •Signs of OHSS (rare with kisspeptin)
- •Allergic reactions
- •Unexpected symptoms
- •As directed by specialist
References
3 StudiesIVF Oocyte Maturation Trigger (2014)
Human | 6.4 nmol/kg SC | Single dose | 95% mature oocytes, 0% OHSS
Landmark study showing kisspeptin-54 effectively triggers oocyte maturation with dramatically reduced OHSS risk compared to hCG.
View StudyHypothalamic Amenorrhea Treatment (2013)
Human | 6.4 nmol/kg SC | Twice weekly | Restored LH pulsatility
Kisspeptin restored pulsatile LH secretion and ovarian function in women with hypothalamic amenorrhea.
Male Hypogonadism Assessment (2011)
Human | 1 nmol/kg IV | Single dose | Diagnostic differentiation
Kisspeptin challenge distinguished hypothalamic from pituitary causes of hypogonadism in men.
Quick Start Guide
Research Disclaimer
Kisspeptin is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Kisspeptin must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Kisspeptin for any purpose. Consult qualified professionals for any research applications.